OM:ALZCUR

Stock Analysis Report

Executive Summary

AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of Alzheimer’s and Parkinson’s diseases.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Share Price & News

How has AlzeCure Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.7%

ALZCUR

0.7%

SE Pharmaceuticals

2.9%

SE Market


1 Year Return

n/a

ALZCUR

-5.3%

SE Pharmaceuticals

9.0%

SE Market

Return vs Industry: Insufficient data to determine how ALZCUR performed against the Swedish Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ALZCUR performed against the Swedish Market.


Share holder returns

ALZCURIndustryMarket
7 Day2.7%0.7%2.9%
30 Day-2.0%-0.8%-0.4%
90 Day-0.1%-9.7%0.3%
1 Yearn/a-3.4%-5.3%13.7%9.0%
3 Yearn/a8.2%2.4%30.5%11.1%
5 Yearn/a2.7%-8.0%66.0%30.7%

Price Volatility Vs. Market

How volatile is AlzeCure Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AlzeCure Pharma undervalued based on future cash flows and its price relative to the stock market?

0.75x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate ALZCUR's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate ALZCUR's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: ALZCUR is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: ALZCUR is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate ALZCUR's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: ALZCUR is good value based on its PB Ratio (0.8x) compared to the SE Pharmaceuticals industry average (3.8x).


Next Steps

Future Growth

How is AlzeCure Pharma expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AlzeCure Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has AlzeCure Pharma performed over the past 5 years?

-85.4%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if ALZCUR's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare ALZCUR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALZCUR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5.7%).


Return on Equity

High ROE: ALZCUR has a negative Return on Equity (-19.18%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ALZCUR is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ALZCUR is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is AlzeCure Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: ALZCUR's short term assets (SEK214.1M) exceeds its short term liabilities (SEK4.4M)

Long Term Liabilities: ALZCUR has no long term liabilities


Debt to Equity History and Analysis

Debt Level: ALZCUR is debt free.

Reducing Debt: ALZCUR has not had any debt for past 5 years.


Balance Sheet

Inventory Level: ALZCUR has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ALZCUR's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALZCUR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ALZCUR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -76.9% each year


Next Steps

Dividend

What is AlzeCure Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%4.8%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate ALZCUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ALZCUR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ALZCUR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALZCUR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALZCUR's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of AlzeCure Pharma's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average board tenure


CEO

Johan Sandin (49yo)

2.8yrs

Tenure

0

Mr. Johan Sandin is the Chief Executive Officer at AlzeCure Pharma AB (publ) since 2017. Mr. Sandin is a behavior pharmacologist within the neurology area with a large academic and industrial experience. H ...


Board Age and Tenure

2.8yrs

Average Tenure

60yo

Average Age

Experienced Board: ALZCUR's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Birgitta Lundvik (52yo)

    Chief Financial Officer

    • Tenure: 1.8yrs
  • Johan Sandin (49yo)

    Chief Executive Officer

    • Tenure: 2.8yrs

Board Members

  • Thomas Pollare (66yo)

    Chairman

    • Tenure: 2.8yrs
  • Ragnar Linder (66yo)

    Director

    • Tenure: 2.8yrs
  • Pirkko Tamsen (60yo)

    Director

    • Tenure: 1.8yrs
  • Annigje Johansson (59yo)

    Director

    • Tenure: 2.8yrs
  • Ellen Donnelly (45yo)

    Director

    • Tenure: 1.8yrs

Company Information

AlzeCure Pharma AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AlzeCure Pharma AB (publ)
  • Ticker: ALZCUR
  • Exchange: OM
  • Founded: 2012
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr158.427m
  • Shares outstanding: 37.77m
  • Website: https://www.alzecurepharma.se

Number of Employees


Location

  • AlzeCure Pharma AB (publ)
  • Hälsovägen 7
  • 7th Floor
  • Huddinge
  • Stockholm County
  • 141 57
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALZCUROM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKNov 2018
AC6DB (Deutsche Boerse AG)YesShare CapitalDEEURNov 2018

Biography

AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of Alzheimer’s and Parkinson’s diseases. The company is developing five drug candidates based on the NeuroRest ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 00:36
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)